Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcrip

Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript

Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript April 30, 2024 Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.17 EPS, expectations were $0.28. EXEL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, ladies and gentlemen, and […]

Related Keywords

, Michael Morrissey , Peter Lamb , Jennifer Chan , Cabo Atezo , Monty Pal , Laura Dillard , Neeraj Agarwal , Joe Catanzaro , Dana Aftab , Broad Institute , Alliance For Clinical Trials In Oncology , Clinical Trials , Scientific Strategy , Human Resources , Exelixis , Amy Peterson , Cabozantinib , Mike Morrissey ,

© 2024 Vimarsana
Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript : Comparemela.com

Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript

Card image cap

Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript April 30, 2024 Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.17 EPS, expectations were $0.28. EXEL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, ladies and gentlemen, and […]

Related Keywords

, Michael Morrissey , Peter Lamb , Jennifer Chan , Cabo Atezo , Monty Pal , Laura Dillard , Neeraj Agarwal , Joe Catanzaro , Dana Aftab , Broad Institute , Alliance For Clinical Trials In Oncology , Clinical Trials , Scientific Strategy , Human Resources , Exelixis , Amy Peterson , Cabozantinib , Mike Morrissey ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.